Drug resistance is one of the trademark features of Cancer Stem Cells (CSCs). We and others have recently shown that paucity of functional death receptors (DR4/5) on the cell surface of tumor cells is one of the major reasons for drug resistance, but their involvement in the context of in CSCs is poorly understood. By harnessing CSC specific cytotoxic function of salinomycin, we discovered a critical role of epigenetic modulator EZH2 in regulating the expression of DRs in colon CSCs. Our unbiased proteome profiler array approach followed by ChIP analysis of salinomycin treated cells indicated that the expression of DRs, especially DR4 is epigenetically repressed in colon CSCs. Concurrently, EZH2 knockdown demonstrated increased expression of DR4/DR5, significant reduction of CSC phenotype such as spheroid formation in-vitro and tumorigenic potential in-vivo in colon cancer. TCGA data analysis of human colon cancer clinical samples shows strong inverse correlation between EZH2 and DR4. Taken together, this study provides an insight about epigenetic regulation of DR4 in colon CSCs and advocates that drug resistant colon cancer can be therapeutically targeted by combining TRAIL and small molecule EZH2 inhibitors.
Introduction
According to global cancer statistics data, colorectal cancer (CRC) is the fourth most common malignancy worldwide, with 1.09 million new incidences diagnosed in 2018 1 . The standard care for CRC patients is surgical resection followed by adjuvant therapy with chemotherapeutics or molecular targeted therapy. The therapy failure in terms of disease relapse and metastasis often results from the presence of drug-refractory cell population, present in highly heterogeneous solid tumors 2,3 . Increased epithelial-mesenchymal-transition (EMT), stemness and cellular-plasticity are major contributory factors for the development apoptosis resistance in cancer cells. Recently, in two different contexts, we have shown that inducing lethal autophagy is an effective strategy to overcome apoptosis resistance in colon cancer 4 and SPINK-1 regulates cellular plasticity and stemness in prostate cancer 5 . The phenotype of drug resistance cells in solid tumors like colon cancer is extensively overlapping with the properties of cancer like stem cells or cancer stem cells (CSCs) that demonstrate enormous cellular plasticity, self-renewal and tumor-initiating capabilities 6 . Gupta et al., in their pioneering work, first identified salinomycin as a potent CSC killer by utilizing high throughput screening approach 7 . Due to its immense clinical potential, this finding itself fueled exponential growth in the literature of salinomycin and CSCs; and some of them proposed its mode of actions in different cancers via alteration of different signaling cascades 8 . Numerous recent studies emphasize the crucial role of epigenetic regulation in modulating various CSC attributes including drug resistance [9] [10] [11] . Therefore, how salinomycin is able to epigenetically target them is still remained elusive. Histone modifications through Polycomb Group (PcG) of proteins have shown to drive stem cell biology via chromatin remodeling, specifically by catalyzing posttranslational modifications on histone proteins via Polycomb Repressive Complex 1 (PRC1) and PRC2 [12] [13] [14] . Enhancer of zeste homologue 2 (EZH2) is the catalytic component of the PRC2 complex that is involved in transcriptional repression of its target gene by tri-methylation of lysine 27 at histone H3 (H3K27) 15 . Seminal studies by Chinnaiyan's group first linked EZH2 with the progression of solid tumors 16, 17 . More recently, EHZ2 has shown to regulate hallmarks of CSC properties like self-renewal, tumorigenic potential and drug resistance in different tumor types 18, 19 . Most important breakthrough is EZH2 inhibitor Tazemetostat (EPZ6438) just received FDA approval for metastatic epithelioid sarcomas.
We and others have shown that paucity of functional DR4/DR5 on the cell surface of colon tumor cells is one of the major reasons for drug resistance in general, but their involvement in the context of drug resistance in CSCs are not known so far [20] [21] [22] [23] . By harnessing CSC specific cytotoxic function of salinomycin, we discovered an unprecedented role of EZH2 in modulating the expression of death receptor in colon cancer. Our unbiased proteome profiler array approach indicated salinomycin mediated regulation of death receptors in colon cancer.
Further molecular insight of death receptor regulation by salinomycin suggests that expression of DR4, DR5 was found to be epigenetically repressed in colon CSCs due to the EZH2 mediated histone hyper-methylation, independent of promoter DNA methylation. Salinomycin or EZH2 inhibitor treatment withdraws H3K27 trimethylation marks from the promoter of death receptors and up-regulates the functional expression of DR4 and DR5 and sensitizes colon cancer cells against TRAIL therapy. Concurrently, in a similar setting, genetic loss of EZH2 resulted in significant reduction in CSC properties in-vitro and in-vivo. Taken together, this study provides a novel link for epigenetic regulation of death receptor in colon CSCs that can be therapeutically targeted in future.
Cell culture and treatment:
Representative colon cancer cell lines DLD-1, RRID: CVCL_0248 (epithelial, non-metastatic colorectal adenocarcinoma),SW-620, RRID:CVCL_0547 (Dukes' type C, metastatic colorectal adenocarcinoma) and LOVO, RRID:CVCL_0399 (grade IV, colorectal adenocarcinoma), HT-29, RRID:CVCL_0320 (colorectal adenocarcinoma) were obtained from American Type Culture Collection (ATCC), USA. Mycoplasma free early passage cells were resuscitated from liquid nitrogen vapor stocks and inspected microscopically for stable phenotype before use. All cell lines used in the study are authenticated by STR profiling. Cells were cultured as monolayers in recommended media supplemented with 10% FBS, 1-X anti-anti (containing 100 μg/ml streptomycin, 100 unit/ml penicillin and 0.25 μ g/ml amphotericin B) and maintained in 5% CO 2 and humidified environmental 37 o C. In all treatments, salinomycin and GSK-343 and EPZ6438were dissolved in cell culture grade DMSO at concentration of 10 mM and Cisplatin 1mg/ml. TSA, 5'-Azacytidine, DZNep, TRAIL and other chemicals were dissolved as per supplier's recommendation. The sub-confluent cells were treated with required doses of compounds in all the experiments.
Cell Viability Assay:
A standard colorimetric SRB assay was used for the measurement of cell cytotoxicity 24 . In this experiment, 10,000 cells of each cell lines were seeded to each well of 96-well plate in 5% serum containing growth medium and incubated overnight to allow for cell attachment. Cells were then treated with test molecule at the required dose and untreated cells received the same volume of vehicle containing medium served as control. After 48 h of incubation, cells were fixed with ice-cold 10% TCA, stained with 0.04% (w/v) SRB in 1% acetic acid, washed and air dried. Bound dye was dissolved in 10mM Tris base and absorbance was measured at 510 nm on a plate reader (Epoch Microplate Reader, Biotek, USA). The cytotoxic effects of compounds were calculated as % inhibition in cell growth as per the formula [100-(Absorbance of compound treated cells/ Absorbance of untreated cells)] X 100.
Flowcytometry staining and analysis:
For Annexin-V and CD133 double staining, cells were trypsinized and washed with 1× binding buffer and then incubated with FITC conjugated Annexin-V (BD Biosciences) for 15 min at room temperature in the dark. After Annexin-V staining, cells were washed with PBS containing 0.1 % FBS, and then incubated with either appropriate isotype control antibody or PE conjugated CD133/1 on ice in the dark for 15 min.
After washing with PBS, cells were acquired in FACS-Calibur TM (BD Biosciences) and analyzed by using FlowJo software (Tree Star Inc, USA). For DR4/DR5 and CD133 dual staining, we used PE conjugated DR4/DR5 and APC conjugated CD133 antibodies along with isotype controls and followed above mentioned protocol for FACS analysis. The ALDEFLUOR kit (StemCell Technologies, USA) was used to assess the population with a high ALDH enzymatic activity. Cells were suspended in ALDEFLUOR assay buffer containing ALDH substrate (BAAA, 1 μ mol/l per 1×10 6 cells) and incubated during 40 min at 37°C. For each sample of cells, an aliquot was treated with 50mmol/L diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor as negative control. Finally, cells were acquired and analyzed by following the same protocol.
Human apoptosis protein array:
Apoptosis array analysis was performed using the Proteome Profiler Human Apoptosis Array Kit (ARY009) from R&D Systems according to the manufacturer's instructions. Briefly, SW620 cells were plated at a density of 1× 10 6 cells in a 60 mm tissue culture dish for 24 hours and then were treated with 10μM concentration of salinomycin. After 24 hours of treatment, cell lysates were prepared by homogenization in lysis buffer 16 (R&D systems) and incubated on ice for 30 min. Lysates were cleared by centrifugation at 14,000 g for 15 min at 4 °C. The protein concentration of the supernatants was measured using the BCA protein assay kit (Pierce) with bovine serum albumin as the standard. Apoptosis array was performed as described previously 25 .
RNA isolation and Reverse Transcription-PCR (RT-PCR) analysis:
Total RNA was prepared using the Pure Link TM RNA Mini kit The cDNA synthesis and PCR were carried out by Verso one-step reverse transcription-PCR (RT-PCR) kit using gene-specific primers and following the manufacturer's protocol, and the detailed procedure as described previously 26 .
The sequence of the oligonucleotide primers used are as follows: for human GAPDH: Primers were designed using Gene Script PCR design software and synthesized by IDT Inc.
The sequence of the various primer sets used in the study is as given in the Supplementary   Table- 1.
Confocal Microscopy
Control and treated cells were fixed with ice-cold pure methanol for 10 min at -20º C followed by blocking with 2% BSA for 1 hour at RT. After overnight primary antibodies (anti-EZH2 and anti-DR5) incubation, cells were washed twice with PBS and incubated with fluorescentconjugated secondary antibodies at RT for 1 hour, followed by DAPI staining for 5 min at RT.
After washing, cells were mounted with anti-fade mounting medium on glass slides and viewed under an inverted confocal laser scanning microscope (Zeiss Meta 510 LSM; Carl 1 0
imaging and data collection. Appropriate excitation lines, excitation and emission filters were used for imaging.
EZH2 knock down by utilizing retroviral transduction:
Control and stable EZH2 cell lines were generated by utilizing retroviral mediated transduction system followed by puromycin selection. Control and EZH2 (cat #24230) knockdown retroviral plasmid were brought from Addgene USA. The Phoenix cell line was used for the generation of retroviral particles using the transfection reagent Lipofectamine 2000.The Phoenix cells were plated in the 6-well plate at 80% confluency. Polybrene (8μg/ml) was added to the viral soup during the transduction matured viral particles into the target cells. Cells were subjected to puromycin selection, and the EZH2 knockdown was confirmed by western blot.
In -vivo studies in xenograft tumor models
All animal studies were conducted by following standard principles and procedures approved by the Institutional Animal Ethics Committee (IAEC) CSIR-Central Drug Research Institute.
Xenograft implantation of colon tumor cells into mice was performed as described earlier 27 . In brief, established stable 1x10 6 DLD-1 control or EZH2 KD cell in 100μl PBS were subcutaneously inoculated in to both flanks of the left and right hind leg respectively of each S4-6-week-old nude Crl: CD1-Foxn1 nu mice. Throughout the study, tumors were measured with an electronic digital caliper at regular interval and the tumor volume was calculated using
(a is the short and b is the long tumor axis). At the end of experiment, mice were sacrificed, and subcutaneous tumors were dissected for further studies.
Several recent reports suggested that salinomycin can target CSCs 7,29 ; but whether its cytotoxic effects are selective to CSCs is not well understood. To study the effect of salinomycin on the CSC population in the colon cancer cells, we have selected colon-specific CSC marker (CD133) and Aldehyde dehydrogenase (ALDH) activity as read out for stemness.
We checked the expression of CD133 and ALDH activity in different colon cancer cell lines through flow cytometry ( Figure 1A and Supplementary Figure 1 ). The FACS histogram overlays suggest that CD133 expression was least in DLD-1 cells whereas, LOVO, SW620 and HT-29 cells show moderate to high stemness properties ( Figure 1A and Supplementary Figure   1 ). To test the effect of salinomycin on particularly CD133+ versus CD133-cells, we try to first adapt FACS Aria based CD133 sorting to isolate both positive and negative cells from DLD-1 colon cancer cell lines and cultured for couple of days and check the CSC integrity of the cells before salinomycin treatment. Unfortunately, we observed that majority of sorted CD133 + cells rapidly converted into CD133cells and quickly lost their CSC integrity (Supplementary Figure 2) , which actually supports the concept of CSC plasticity reported by Chaffer et.al, in her classic paper 30 . As CSC sorting in colon cancer cell lines did not offer us right kind of model system, we focus our study on CSC enriched colon cancer cells. Since SW620 cells were showing higher CSC activity, we selected this cell line to study the effect of Salinomycin treatment on CD133 and ALDH activity. Here, we observed that salinomycin significantly reduced CD133 expression as well as ALDH activity in SW620 cells. In contrast, common chemotherapeutic drug cisplatin failed to do so ( Figure 1B and 1C ).
Next, by utilizing this cellular model system with differential level of stemness, we sought to determine the in-vitro cytotoxic efficacy of both salinomycin and cisplatin in DLD-1 (CSC low ) and SW620 (CSC high ) cells by standard SRB assay. Interestingly, we observed that salinomycin posed robust cytotoxic effects against both the cell types whereas; cisplatin displayed cytotoxicity only against CSC low DLD-1 cells ( Figure 1D ). Transformation of anchorage-dependent (2D) growth to anchorage-independent (3D) growth or spheroid formation is a well-established characteristic feature of CSC development. Here, we first tested multiple colon cancer cells for spheroid formation and checked their stemness/differentiation status in 2D to 3D conditions. CSC low DLD-1 cells were found to be most suitable for our purpose as it showed reverse regulation in stemness (CD133) marker versus colonic epithelial differentiation (cytokeratin 20 or CK20) during 2D-3D transformation as observed by Western blot analysis ( Figure 1E ). So, we sought to determine the effect of both salinomycin and cisplatin in 2D-3D transformation of DLD-1 cells.
Interestingly, we observed that salinomycin effectively attenuated the spheroid formation, whereas, cisplatin treatment resulted in even larger spheroids instead of its inhibition ( Figure   1F ). We checked the viability control and treated cells, isolated from colonies and confirmed that salinomycin was able to induce cell death in spheroid colonies, whereas, cisplatin remained ineffective in killing CSCs ( Figure 1G ). So, these results together suggest that unlike chemotherapeutic drug cisplatin, salinomycincan effectively induces cytotoxicity to colon CSCs. Differential cytotoxic effect of salinomycin and cisplatin on colon CSCs prompted us to investigate whether these two can induce apoptosis in colon CSCs. To study the effects of salinomycin and cisplatin specifically on CSCs, we double stained our treated and control cells with CD133 (as stemness marker) and Annexin-V (as early apoptotic marker) and analyzed by flow cytometery to study the event of early apoptosis in stem cell (CD133 + ) compartment.
Interestingly, in the case of salinomycin treatment, we found a marked amount of Annexin-V + early apoptotic cells in CD133 + , but cisplatin failed to induce early apoptosis (Annexin-V + ) in the same population ( Figure 1H ). Altogether, these results indicate that unlike the conventional chemotherapeutic drug cisplatin, salinomycin inhibits CSC properties and promotes apoptosis in colon CSCs.
Salinomycin selectively up-regulates the expression of functional DR4 and DR5 in colon CSCs and sensitizes them for TRAIL-induced apoptosis
After confirming that salinomycin induces apoptosis in colon CSCs (4, 17), we next explored the involvement of specific pathway for salinomycin induced apoptosis by using human apoptotic proteome profiler array (18). Array results in control versus salinomycin treatment indicate a change in the level of multiple proteins (Figure 2A -2B). The table shown in Figure   2A represents the identity of individual spots on the protein array platform. Based on densitometry of corresponding spots, we prepared a heat map to show relative changes in the level of corresponding protein ( Figure 2B ). Here, we found a marked increase in the level of DR4 and DR5 proteins in response to salinomycin treatment whereas; there was no change in expression of other signatory proteins like cytochrome C, Bax, and Bcl2 ( after 12 hours pre-treatment of salinomycin in both SW620 and LOVO cells which are classically known TRAIL-resistant cells. Here, we found that compared to respective controls, a short exposure of minimal doses (1, 2.5 μM) of salinomycin drastically increased the sensitivity of these cells towards TRAIL-mediated apoptosis ( Figure 2E ). Together, these data confirmed that salinomycin increases functional protein expression level of DR4 and DR5 on the cell surface of the colon CSCs and able to induce the apoptosis in the presence of TRAIL.
Salinomycin up-regulates the expression of DR4 and DR5 by targeting epigenetic modulator EZH2
To investigate the molecular mechanism of salinomycin driven DR4 and DR5 up-regulation;
we first, determined the effect of salinomycin in DR4 and DR5 transcription. So, we performed the RT-PCR in-vehicle control, and salinomycin treated SW620 cells. Our RT-PCR result suggests that salinomycin significantly up-regulates the mRNA expression of both DR4 and DR5 as compared to control ( Figure 3A ). Next, we analyzed whether salinomycin mediated induction in the expression of DR4/DR5is mediated by targeting of transcriptional regulators of DR4/DR5 genes. P53 and SP1are known to act as an activator, while YY1 acts as a repressor of DR4 and DR5 gene transcription 31-34 Here, we determine the expression of P53, SP1 and YY1 in vehicle control and salinomycin treated SW620 cells using Western blot.
Surprisingly, our Western blot analysis of control and salinomycin treated cells indicates that
there was no change in the SP1 level whereas p53 level was decreased after salinomycin treatment ( Figure 3B ).
Similarly, there was no significant change in the YY1 level. As we did not observe any significant difference in the expression of the above-mentioned transcription factors following salinomycin treatment, we focus on possible epigenetic regulators of death receptors, if any.
Therefore, we analyzed whether salinomycin target any specific epigenetic modulator which might be involved in the regulation of DR4/ DR5 expression. In this direction, we first, examine the expression of DR4/DR5 in SW620 cells treated with different epigenetic inhibitors like HNMT inhibitor 3-DeazaneplanocinA (DZNep), DNMT inhibitor 5'-Azacytidine (5-AZA) and HDAC inhibitor Trichostatin A (TSA) using western blot.
Interestingly, the western blot data of control and salinomycin treated cells reveal that the selective inhibition of HNMT protein EZH2 but not DNMT or HDAC inhibitors resulted in upregulation of both DR4 and DR5 proteins in SW620 cells ( Figure 3C ). As DZNep treatment selectively promotes induction of death receptors, we checked the effect of salinomycin on expression of EZH2 and detected significant reduction of EZH2 following salinomycin treatment as compared to control in SW620 and HT-29 cells ( Figure 3D and Supplementary   Figure 4 ). Next, we assessed the expression of EZH2 and its functional enzymatic product H3K27me3 in control and salinomycin treated SW620 cells using confocal microscopy. Here, we observed that salinomycin robustly decreased the level of EZH2 and H3K27me3 compared to control ( Figure 3E , left and middle panel) indicating that it delineates severe impairment of EZH2 functionality. Next, to understand the direct correlation between EZH2 and DR5 at a single-cell level, we simultaneously stained control and treated SW620 cells with EZH2 and DR5, and analyzed their expression together by using confocal microscopy ( Figure 3E , right panel). Here, we found that salinomycin treatment not only decreased the EZH2 level both in the cytosol and nucleus but also increased the DR5 expression in the same population of cells.
These results indicate that salinomycin inhibits EZH2 function which may result in the induction of DR4/DR5 in colon CSCs.
Genetic and pharmacological inhibition of EZH2 results in up-regulation of DR4 and DR5 in the colon CSCs
Based on our confocal microscopy results, we hypothesized that EZH2 enzymatic activity regulates the expression of DR4/DR5 genes. In our preliminary observations, we used DZNep as an EZH2 inhibitor but it is known to have off-target effects. To rule out the off-target effects of EZH2 pharmacological inhibitors, here we selected two potent EZH2 inhibitors, i.e.
GSK343 and EPZ6438, having completely different structural pharmacophores to validate our biological observations associated with it 35 . We treated SW620 cells with the vehicle control and two doses (1 and 5µM) of GSK-343 for 24 hours and analyzed the expression of EZH2, H3K27me3, DR4, and DR5 by Western blot. As shown in Figure 3F (left and right panel), compared to vehicle-treated SW620 cells, GSK-343and EPZ6438 treatment reduced the expression of H3K27me3 and simultaneously markedly increased expression of both DR4 and DR5. Similar results were obtained by using EPZ6438 in HT-29 cells (Supplementary Figure   5 ). Further to check whether EPZ6438 mediated increase in DR4/DR5 was at the transcriptional level or not, we performed real-time q-PCR analysis in EPZ6438 treated SW620 cells. We found a substantial mRNA increase in both DR4 and DR5 genes ( Figure 3G) following EZH2 inhibitor treatment. The q-PCR analysis also suggests that endogenous mRNA expression of DR4 gene is significantly lower than DR5 in control SW620 cells that could be the result of predominant epigenetic transcriptional suppression of the DR4 gene over DR5. To confirm our pharmacological inhibitor-based observations, we utilized genetic knockdown approach to examine EZH2 dependent DR4 and DR5 regulation. Here, we made stable EZH2 knockdown SW620 cells by utilizing the retroviral transduction system, and then we analyzed the expression of EZH2, H3K27me3, DR4, and DR5 by Western blot. Compared to the control, EZH2 knockdown resulted in a marked decrease in H3K27me3 level with significant up-regulation of both DR4 and DR5 proteins ( Figure 3H ).
As the previous series of data were generated using whole-cell population of SW620, now we sought to determine the impact of EZH2 inhibitor in regulation of death receptors in CSC compartment. Here, we assessed the effect of GSK-343 on cell surface expression of DR4/DR5, particularly in colon CSCs. Similar to salinomycin, we also found functional inhibition of EZH2 by GSK-343 resulted in marked increase in the surface expression of DR4 and DR5 in CD133 + compared to control ( Figure 3I ; left and right panels). Next, we sought to specifically determine the effect of EZH2 inhibitor in inducing apoptosis of colon CSCs. Using previously established strategy, we again double-stained control and GSK-343 treated SW620 cells for CD133 and Annexin-V followed by Flowcytometry analysis to study the event of early apoptosis in CSC (CD133 + ) compartment. Interestingly, it was observed that like salinomycin, EZH2 inhibitor treatment caused a prominent increase in Annexin-V + early apoptotic cells in CD133 + cells ( Figure 3J ). Overall, these results clearly indicate that EZH2 directly regulates the expression of DR4 and DR5 by epigenetic suppression of their expression in colon cancer stem cells.
By targeting EZH2, salinomycin withdraws H3K27me3 marks near the promoters of DR4 and DR5
In the previous experiments, we observed Salinomycin and EZH2 inhibitor EPZ6438
transcriptionally regulates the expression of DR4 and DR5.EZH2 is known to suppress its target gene by trimethylating H3K27 in the vicinity of their promoters 36 . Therefore, we performed the chromatin immunoprecipitation (ChIP) assay to delineate the H3K27me3 marks near DR4 and DR5 genes. We designed walking primers for DR4 and DR5 from the sliding window of 1500 bases upstream and downstream of transcription start site (TSS) by using the UCSC genome browser (https://genome.ucsc.edu/). We first examined the enrichment of Figure   4A ).
Further, we separately treated SW620 cells with 5 μM of salinomycin and 10 μMofEPZ6438
and performed the ChIP assay and quantitatively analyzed the results by q-PCR. Our real-time q-PCR results show that both salinomycin and EPZ6438 were able to strongly eliminate the enrichment H3K27me3 marks from -27, -414, -804, and -1217 sites as compared to control ( Figure 4B-4G ). Of note, at certain sites like -1476 and +522, the EPZ6438 was found to be more potent to eliminate H3K27me3 marks. Subsequently, a similar experiment was performed for DR5 to observe the distributions of H3K27me3 marks near its promoter. The ChIP-q-PCR results of DR5 revealed that the major enrichment marks of H3K27me3 were present near the primer flanking region at position +209 as compared to the other sites ( Figure 4H ). Next, we analyzed the potential of both salinomycin and EPZ6438 to remove the H3k27me3 marks at DR5 promoter. Here, we found the elimination of H3K27me3 marks at a lesser number of sites that includes -854, -1302, and +475 ( Figure 4I-4O 
EZH2 knockdown attenuates CSC properties in-vitro and in-vivo
To validate our in-vitro observations into in-vivo, we first developed DLD-1 xenograft model as it was observed to faithfully recapitulate functional CSC properties during 2D to 3D transformation. Utilizing the same model, we made multiple attempts to observe the in-vivo antitumor efficacy of salinomycin. Unfortunately, instead of efficacy, we found salinomycin treatment is extremely toxic to animals even at low dose as observed in earlier findings 37 .
2mg/kg intra-peritoneal daily dose of salinomycin resulted more than 20% weight loss in nude mice in a week time. Therefore, we decided to dissect the direct role of EZH2 in modulating CSC properties in colon cancer in-vivo, as EZH2 is the most viable drug target for salinomycin.
Before going to in-vivo experiments, first we explored the impact of loss of EZH2 function in spheroid formation. So, we performed retroviral transduction to knock down EZH2 in DLD-1 cell line and performed Western blot analysis to confirm knockdown efficiency ( Figure-5A ).
Next, we allowed both control vector and EZH2 knockdown cells to grow in the 3D culture condition. We observed that EZH2 knockdown markedly attenuates the spheroid formation, whereas, control cells formed the ideal spheroid colonies (Figure-5B ). The trypan blue staining showed that the cell viability in EZH2 knockdown spheroid was significantly lower than that of control cell-derived spheroids (Figure-5C ). The tumorigenic potential of cancer cell is another hallmark feature of CSC. To understand the influence of EZH2 in modulating in-vivo tumorigenic potential, we inoculated control and EZH2 knockdown DLD-1 cells at two different dilutions (0.5x10 6 and 1x10 6 ) in the right and left flank of same mice (n=3), respectively.
Interestingly, at lower dilution (0.5x10 6 ), EZH2 knockdown DLD-1 cells failed to develop tumors in each of the three cases, whereas, the same number of control DLD1 inoculation resulted in prominent tumors in all three flanks suggesting strong inhibition of tumorigenic potential of colon cancer cells under EZH2 knockdown condition. In case of other dilution, EZH2 KD cell-derived tumors are smaller than control cell-derived tumors as demonstrated in representative pictures (Figure-5D ). As observed in Figure 5E and 5F, inoculation of 2 million EZH2 KD cells resulted in significant (p<.01) reduction in tumor volume and weight as compared to control cell insulated tumors. Together, our results demonstrate that EZH2 plays a critical role in modulating CSC properties in vitro and in vivo in colon cancer.
To understand the pathophysiological significance of our finding in context of human colon cancer, we exploited TCGA database to find out clinical correlation between EZH2 and death receptors. Interestingly, we observed a strong inverse correlation between EZH2 and DR4 expression in most of the colon cancer patient samples ( Figure 5G) , whereas, such inverse correlation is missing in case of DR5 expression (data not shown) again supporting our previous observations that EZH2 mediated DR4 regulation is predominant than DR5. Together, our results demonstrate that EZH2 can be therapeutically targeted to reduce CSC properties and DR4 expression may be a critical read out for inhibition of EZH2 function in human colon cancer.
Discussion
Though salinomycin has never positioned as a drug for cancer therapy, its discovery in the context of CSC targeting agent ignited new possibilities for finding novel molecular cues to tame therapy-resistant cancer cells. However, most of the studies for CSC specific cytotoxic function were based on genetically manipulated cells to develop a phenotype like CSCs in multiple cancers 7,38 . For example, Gupta et al. enriched CSCs by loss of E-Cadherin function and tested the specificity of salinomycin to kill CSCs. In the course of dissecting salinomycin's CSC specific cytotoxic function in physiologically relevant settings, we observed that salinomycin targets both CSC and non-CSC population which is corroborative for its immense toxic nature 37 . Nevertheless, the unique feature of salinomycin is that unlike standard chemotherapeutic drugs such as cisplatin, it can pose robust cytotoxic effects to cancer stem like cells.
We utilized this unique property of salinomycin to elucidate the mechanistic insight to target cancer stem cells or drug refractory cells. Earlier studies elucidated the influential role of high ALDH activity in drug resistance in general and high CD133 expression is associated with stemness in colon cancer 39, 40 . In alignment with previous results, we also observed the same reflection that salinomycin inhibits the expression of CD133 as well as ALDH activity in colon cancer cells. The flow-cytometry data demonstrated that salinomycin not only has the potential to induce apoptosis in CD133 enriched cells but also reduces CD133 expression to convert high CD133 enriched cells into low CD133enriched cells. Indeed, salinomycin can differentiate the CSCs to non-CSCs and supports the basic concept of CSC plasticity 25, 30, 40, 41 .
Recent studies suggest that the phenotypic changes through salinomycin treatment have linked with various signal transduction pathways like Wnt, K-RAS and Hedgehog signaling 42-44 . In addition, salinomycin targets various cellular processes in cancer which includes autophagy induction, mitochondrial impaired function, and depletion in ATP production. Besides, salinomycin treatment increases the production of reactive oxygen species (ROS) together with sequestration of iron in lysosomes, which induce ferroptosis in breast CSCs [45] [46] [47] [48] [49] Several studies have demonstrated that salinomycin had synergistic effect with TRAIL therapy by DR5 modulation in glioma and ovarian cancers 55, 56 . Earlier finding regarding PRC2 mediated DR5 regulation is actually supporting our current observations 57 . However, histone methylation mediated epigenetic regulation of DR4 and the ability of salinomycin for TRAIL sensitization in colon CSCs was not reported so far. Though very limited information is present on the epigenetic regulation of DR4/DR5, prior studies examined that DR4 promoter was hyper-methylated in astrocytic glioma and DNMT inhibitor 5-aza-2-deoxycytidine treatment rescued the expression of DR4 in a total population of different glioma cell lines 58 . However, in colon cancer cells, we did not find any correlation between promoter DNA methylation and DR4 expression. In our case, the treatment with 5-aza-2-deoxycytidine did not affect the expression of DR4/DR5 ( Figure 3C ). In fact, we analyzed the effect of direct modulation of all three epigenetic modifications including DNA methylation, histone methylation and histone acetylation on DR4/DR5 expression in an unbiased manner. This led us to discover that only histone methyl transferase EZH2 regulates the DR4/DR5 expression at transcriptional level.
Thus, epigenetic landscapes are highly dynamic and context-dependent. The several reports suggested that EZH2 suppressed the expression of genes by tri-methylation of histone H3 at lysine 27 residue near the promoter of the target genes 19 . In support with our findings, Yang Interestingly, it has been shown that EZH2 knockdown resulted in loss of drug-resistant side population or SP (CSC marker) and other CSC properties in ovarian cancer 62 . Another study showed that EZH2 is required for the stem cells regulation and tumorigenesis in skin cancer 63 .
In current study, EZH2 knock-down attenuated spheroid formation and suppressed the tumorigenic potential of colon cells in mouse xenograft model. Altogether, these findings delineate the central role of EZH2 in regulation of CSC phenotype, drug resistance and tumorigenesis and indeed, strongly advocating the immense potential of EZH2 inhibitors to overcome therapy resistance in cancer, especially by targeting CSC population. As a matter of fact, several EZH2 inhibitors like EPZ6438 and GSK126 are rapidly moving forward to Phase-I and II clinical trials against lymphoma and solid tumors 64 . In summary, our present findings provide mechanistic insights for the drug resistance properties in colon CSCs and suggest possible therapeutic interventions to overcome it. Nonetheless, it is the first report regarding the link between EZH2 and DR4 in colon cancer stem cells.
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